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Background and objectives: The frequency of Type 1 diabetes (T1D)-related autoantibodies was determined in
children with autoimmune hepatitis. However, the incidence of autoimmune hepatitis related autoantibodies in
children with T1D has been poorly investigated. The aim of the present cross sectional prospective study was to
determine the occurrence of autoimmune hepatitis-related autoantibodies in children with T1D.
Methods: Children with T1D following in diabetic clinic in our center were screened for existence of liver related
autoantibodies from November 2010 to November 2011. The patients’ sera were analyzed for the existence of
autoantibodies such as anti-nuclear antibody, anti-smooth muscle antibody, and anti-Liver Kidney microsomal
antibody, using enzyme linked immunoassay and indirect immunofluorescence methods. A titer of anti-nuclear
antibody ≥1/40 was considered positive and titer of < 1/40 was considered negative. Anti-liver kidney microsomal
antibody titer of < 3 U/ml was considered negative, 3 – 5 U/ml borderlines, and > 5 U/ml was considered positive.
Results: 106 children with T1D have been examined over a one-year period: age ranges between 8 months to
15.5 years, sixty two patients were females. Autoantibody screen revealed a girl with positive anti-liver kidney
microsomal antibody (1%) and 8 children had positive anti-nuclear antibody (7.5%), without clinical, biochemical
or radiologic evidence of liver disease. None of the patients had positive smooth muscle antibody.
In conclusion: Anti-liver kidney microsomal antibody is rarely found in sera of children with T1D; the clinical
significance of which is unknown.
Keywords: Type 1 diabetes, Liver autoantibodies, Antinuclear antibody, Smooth muscle antibody, Anti-liver
kidney microsomal antibodyIntroduction
Type 1 diabetes (T1D) is a disorder of glucose metabolism
that results from insulin deficiency secondary to auto-
immune destruction of insulin – secreting β cells. The
finding of organ–specific autoantibodies in patients with
T1D discloses the existence of a wide spectrum of im-
munological diseases. Fifteen to 30% of patients with T1D
have autoimmune thyroiditis, 4-9% have celiac disease,
and 0.5% have Addison’s disease [1]. Autoimmune hepa-
titis (AIH) has been reported to occur in patients with
T1D [2-7]. The frequency of T1D-related autoantibodies* Correspondence: aa_alhussaini@yahoo.com
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article, unless otherwise stated.was determined in children with AIH: islet cell antibodies
and insulin autoantibodies were found in 60.7% and 18.5%
of patients with AIH, respectively [4]. However, the
co-occurrence of AIH and the frequency of AIH type 1
related auto-antibodies, such as anti-nuclear antibody
(ANA) and anti-smooth muscle antibodies (SMA), and
anti-Liver/Kidney microsomal (LKM-1) antibodies in
AIH type 2, in patients with T1D has only been
recently investigated in very limited number of studies
[8,9]. In a retrospective study, Allen at al. had screened
adults with T1D for presence of organ specific auto-
antibodies; 2 out of 261 (0.8%) were positive for SMA
and none was positive for LKM-1 antibody [8]. The
serologic tests used in this study to detect SMA and
LKM-1 antibodies were not mentioned. In a controlled
study in adults, Heras et al. found that19 of 70 patientstral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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of 28 patients with type 2 diabetes (14%) and 4 of 20
healthy controls (20%) [P < 0.001] [9].
Our cross sectional prospective study is the first to report
on frequency of AIH related autoantibodies in children
with T1D.
Patients and methods
Children with T1D in follow up in diabetes clinic in
our tertiary care center were consecutively enrolled
into the study over the period from November 2010 to
November 2011. Type 1 diabetes was diagnosed by the
onset of hyperglycemia, the absolute dependence on
insulin treatment for survival, and by the presence of
severe deficiency of insulin secretion (i.e., very low or
undetectable fasting C–peptide levels) and of anti-islet
cell auto-antibodies. We excluded children with other
disease that might primarily affect the liver. The study
has been conducted after parental consent. The follow-
ing have been collected: age, sex, age of onset of T1D,
duration of T1D, and individual and family history of
autoimmune diseases. Blood has been collected and
the sera were used for the examination of the presence
or absence of the following autoantibodies:
A- Anti-nuclear antibodies screening
Anti-Nuclear Antibodies were detected using DiaSorin
kits Immunofluorescence assay (DiaSorin, Saluggia, Italy),
Serum samples were diluted to 1:40 then added for 30 mi-
nutes to the Hep2 cells fixed on the slides. After washing,
the FITC-labeled conjugate was added for 30 min incuba-
tion. After washing step, the mounting media was added
and slides were cover slipped and analyzed for nuclear
patterns using florescent microscope. The observation of
positive staining with specific pattern on the substrate
indicates the presence of ANA in the test sample. A titer
of ANA ≥1/40 was considered positive and titer of < 1/40
was considered negative. To rule out systemic lupus ery-
thematosus (SLE), all positive samples were screened for
double-stranded DNA (dsDNA) using LIAISON dsDNA
chemiluminescence assay (DiaSorin, Saluggia, Italy).
B- Anti-smooth muscle antibodies (SMA)
Anti-Smooth Muscle Antibodies were detected using
solid phase enzyme immunoassays using INOVA Diag-
nostics (San Diego, CA) ELISA kit. Antigens coated 96
wells plates were incubated for 30 minutes with calibra-
tors, positive and negative controls and diluted serum
sample specimens. During incubation, antibody present
in the test sample binds to the coated well. Following
the 30 minutes incubation, the wells were washed and
horseradish peroxidase-conjugate anti-human IgG was
added to the wells. Then the substrate was added for
30 minutes and the reaction stopped. The optical densitywas measured by spectrophotometer. The cutoff was <20
U/IU and whenever the result was positive, we per-
formed F-actin IgG enzyme linked immunoassay kit
from INOVA Diagnostics (San Diego, CA) as confirma-
tory test.
Alternatively, anti-SMA screening was done by Im-
munofluorescence assay using INOVA Diagnostics (San
Diego, CA) kit, serum sample was diluted to 1:20 then
added on a slide and incubated for 30 minutes. After
washing, the FITC-labeled conjugate was added for
30 min incubation. After 10 min washing step, the
mounting media was added and the slides were cover
slipped and viewed for fluorescent patterns under flores-
cent microscope. Observation of specific patterns on the
substrate indicates the presence of anti-SMA in the test
sample. A titer of Anti-SMA > 1/20 was considered posi-
tive and titer of < 1/20 was considered negative. Any
time the results were positive, a confirmatory assay was
done using anti-F-actin autoantibodies screening using
enzyme linked immunoassay kit from INOVA Diagnostics
(San Diego, CA).
C- Anti-liver/kidney microsome (LKM-1) antibodies
Anti-Liver/Kidney Microsome antibofies were detected
using ELISA kit from DiaSorin (DiaSorin, Saluggia, Italy).
LKM-1 Antibodies were detected by solid phase enzyme
immunoassays. Antigen precoated 96 well plates were in-
cubated with calibrators, controls and serum specimens.
Then, horseradish peroxidase-conjugated anti-human IgG
was added to the wells. The substrate was added, the reac-
tion stopped and auto-antibodies were measured using a
spectrophotometer plate reader. LKM-1 antibody titer
of < 3 U/ml was considered negative, 3 – 5 U/ml border-
line, and > 5 U/ml was considered positive. Positivity for
LKM-1 antibody was an indication to screen for anti-
HCV antibody.
Cu-off values for the detection of the autoantibodies
in this study were used as recommended by the manu-
facturers and validated by serology laboratory. Children
who tested positive for any of the above autoantibodies
have undergone further evaluation for the presence of
liver disease including: physical examination for hepato-
megaly (by measuring the distance between the upper
and lower borders of the liver at mid-clavicular line
using a tape measure), blood tests for liver function
tests, total serum immunoglobulin, complement C3 and
C4, and ultrasound of liver. The length of the liver was
measured from uppermost portion of the dome of dia-
phragm to the inferior tip. Length of liver above stand-
ard deviation (SD) of mean for normal liver size in
children [10] was reported as hepatomegaly. Uniform
pattern of medium strength echoes from liver was con-
sidered as normal whereas increased strength of echoes
resulting into marked liver-kidney echogenic discrepancy
Table 2 Patients with T1D and positive autoantibodies





1 4 F ANA 1/640 Celiac disease
2 6.5 F ANA 1/160 None
3 11 F ANA 1/80 None
4 6 F ANA 1/640 None
5 15 M ANA 1/80 None
6 7.5 M ANA 1/320 None
7 9 M ANA 1/80 None
8 7.5 F ANA 1/80 None
9 6 F aAnti-LKm 6.8 U/ml None
T1D: Type 1 diabetes; ANA: Anti-nuclear antibody; Anti-LKm: Anti-liver kidney
microsomal antibody; F: Female, M: Male; anormal anti-LKM1 = 3–5 U/ml.
Al-Hussaini et al. Diabetology & Metabolic Syndrome 2014, 6:38 Page 3 of 5
http://www.dmsjournal.com/content/6/1/38and poor definition of hepatic veins, portal vein, and
crus of diaphragm was considered as increased echo-
genicity of liver. Liver biopsy was indicated if there is
any of the following: hepatomegaly, hyperechogenic liver
on ultrasound or elevation of ALT (normal, 30–65 IU/L)
and AST (normal, 15–37 IU/L) > 1.2 times of normal
values. Patients with positive AIH–related auto-antibodies
but normal ALT and AST and no abnormal finding on
ultrasound were not candidates for liver biopsy but were
followed up regularly in the clinic with repeated functional
liver tests and autoantibody every 6 months.
The study was approved by the review board at King
Saud Medical City and had been performed in accord-
ance with the ethical standards laid down in the 1964
Declaration of Helsinki and its later amendments.
Results
Over the one-year study period, 107 children with T1D
were identified. One of them has β-thalasemia major
and hepatomegaly so was excluded from the study; 106
children with T1D were investigated. The demographic,
clinical, and biochemical characteristics of the 106 chil-
dren are shown in [Table 1]. Seven patients were newly
diagnosed with T1D. Screening of diabetic children for
presence of AIH-related autoimmune markers revealed
the following: 8 had high ANA titer (7.5%), and one was
positive for LKM-1 antibody (1%) [Table 2]. All of the
ANA positive patients were negative for dsDNA. None
of these patients had hepatomegaly, hyperechogenic liver
on ultrasound or elevation of ALT and AST > 1.2 times
of normal values; a criterion we have set in our study
protocol to justify doing liver biopsy. All of the patients
had normal serum immunoglobulin G. All ANA positive
patients demonstrated speckled immunofluorescence pat-
tern (Figure 1). Only patient 1 has concomitant autoimmuneTable 1 Clinical and laboratory characteristics of 106
children with T1D
Patients (n = 106)
Mean ± SD
Age (year) 8.5 ± 2.8
Gender (female/male) 62/44
Age at diagnosis of T1D (year) 6.3 ± 2.9
Duration of diabetes (year) 2.2 ± 2.1
Body mass index (kg/m2) 16.5 ± 3.4
HbA1c (%) 10.7 ± 2.4
ALT (U/L) (normal, 30–65 IU/L) 28 ± 8.3
AST (U/L) (normal, 15–37 IU/L) 25.7 ± 10.4
Serum cholesterol (normal 3.65–5.15 mmol/L) 4.16 ± 0.75
Serum triglyceride (normal 0–1.7 mmol/L) 1.02 ± 1.3
ALT = Alanine aminotransferase; AST = Aspartate aminotransferase;
HbA1c = Glycosylated hemoglobin; T1D = Type 1 diabetes.disease with positive anti-tissue transglutaminase antibody of
109 U/ml and biopsy proven celiac disease.
Two patients initially had a weakly positive SMA but
both showed negative results on repetition after 6 months.
The patient with positive LKM-1 antibody was non-
reactive to anti-HCV antibody, and repeat of the test in
6, 12, and 18 months demonstrated a persistently posi-
tive LKM-1 antibody.Discussion
The major finding of our study is the rare finding of
positive LKM-1 antibodies in one child out of 106 chil-
dren with T1D (1%). Eight more patients have been
identified to have high titers of ANA.
Patients with T1D show a high prevalence of auto-
immune aggression against organs like thyroid gland,
small bowel, adrenal gland, and gastric mucosa which
documents the autoimmune dysregulation in such pa-
tients. Fifteen to 30% of patients with T1D have auto-
immune thyroiditis, 4-9% have celiac disease, 0.5% have
Addison’s disease, [1] and 20% have parietal cell anti-
bodies [11]. The presence of organ specific autoanti-
bodies (thyroid peroxidase and thyroglobulin antibodies
with autoimmune thyroiditis, EMA and TTG autoantibodiesFigure 1 Immunofluorescence staining. (A) Speckled
immunofluorescence pattern of anti-nuclear antibody, (B) Healthy
control.
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Addison disease) can precede the development of overt
disease, [1] therefore these organ specific autoantibodies can
provide a simple way to screen for autoimmunity and can
predict the development of autoimmune disease in a suscep-
tible population.
Autoimmune liver disease, particularly AIH type 2, has
been reported to develop in patients with T1D, and vice
versa [3-7]. The frequency of T1D-related autoantibodies
was determined in 28 children with AIH: islet cell anti-
bodies and insulin autoantibodies were found in 60.7%
and 18.5% of patients, respectively; [4] none of these
patients developed T1D after 3 – 9 years of follow up.
Anti-glutamic acid decarboxylase antibodies were present
in only one patient who developed T1D after 3 years [5].
On the other hand, the frequency of AIH related auto-
antibodies (ANA and SMA in AIH type 1, and Anti-LKm
in AIH type 2) in patients with T1D has been poorly in-
vestigated in adults [8,9] and data are lacking in children.
LKM1 autoantibodies are directed against cytochrome
P450 2D6 (CYP2D6), an enzyme expressed by hepatocytes
[12]. Carboxypeptidase H (CPH), a candidate molecular
target in T1D, share sequence similarity to the second
major LKM epitope on CYP2D6. The second major
epitope of CYP2D6 (CYP2D6321–351) shares a common
amino acid motif with CPH33–51 [3]. This data suggest
that autoimmunity to a tissue specific autoantigen may
involve other organs, expressing proteins that share se-
quence similarity to the initial autoantigen, by a cross
reactive immune mechanism, and may lead to clinic-
ally apparent autoimmune disease in some susceptible
individuals. Homologies also exist between CYP2D6
and the genome of HCV, and cross reactivity may ac-
count for anti-LKm in as many as 10% of patients with
HCV infection [13]. Our study identified positive Anti-
LKm antibodies in a 6 year-old girl with T1D (1%), in
absence of clinical or biochemical evidence of overt
liver disease. This finding may be the result of molecu-
lar mimicry between CPH in T1D and the target of
LKm-1 antibody (CYP2D6), leading to a cross reactive
immune response. The main target in AIH type 2 is an
amino acid region on CYP2D6 that lies between pep-
tides 257–269; [14] immunreactivity associated with
HCV is usually directed against diverse epitopes of
CYP2D6 [11]. In T1D, autoantibodies to islet cell com-
ponents are present many years before the onset of
overt disease and are associated with higher risk of de-
veloping T1D [15]. Whether our patient with T1D, but
reactive to LKM-1 antibodies, will eventually develop
overt AIH type 2 remains to be seen. Screening for
type of CYP2D6 epitopes, a procedure that we can not
do in our laboratory, can distinguish the antibody sub-
types and may help verifying the clinical significance of
the antibody detected. Long term, prospective largerstudies are needed to identify the natural history of
autoimmunity against the liver in patients with T1D.
ANA and SMA are clues for the diagnosis of AIH type
1. They may be consequences of liver injury rather than
the cause. They typically lack disease specificity, fluctuate
in titer, and variably appear and disappear in individual
patients [16]. Eight of our patients with T1D demon-
strated high ANA titers without SMA positivity or a clin-
ical or biochemical evidence of liver dysfunction. Thirteen
percent of patients with AIH type 1 have only ANA at
presentation and SMA develop later in 50% of patients
[17]. Interpretation of the significance of ANA reactivity
in our patients should be tempered by the fact that ANA
reactivity, albeit in low titer, is commonly seen in sera
from normal individuals [18]. The presence of autoanti-
bodies, regardless of the titer, does not establish a diagno-
sis or justify treatment if not supported by other findings
[17]. It is possible that autoimmune dysfunction in pa-
tients with T1D could have contributed to ANA reactivity,
as systemic non-liver autoimmune diseases, like systemic
lupus erythematosus, rheumatoid arthritis, Sjogren’s syn-
drome or other connective tissue diseases, are a well-
recognized causes of ANA positivity [19]. However, it
seems unlikely that any of the ANA-positive patients in
this study have sub-clinical systemic lupus erythematosus
as all were anti-double stranded DNA negative. Long-
term follow-up of the entire autoimmune spectrum of
ANA positive patients, especially those with titres >1/320
is required. This will allow us to determine whether the
antibodies are transient findings, following any epigenetic
antigenic stimulus or a precursor of an autoimmune sys-
temic disease of pathogenic prognostic significance. Larger
confirmatory studies are required to further evaluate the
findings of this study.
An important limitation of our study is not testing for
other serological markers of autoimmune hepatitis: anti-
soluble liver antigen and anti-liver cytosol type 1 [20].
Therefore, future studies should consider testing for
complete panel of AIH-related autoantibodies. Another
limitation is the small sample size and lack of a control
group to help understand how specific our findings to
T1D.
In conclusion
Reactivity to anti-LKm1 and ANA in sera of patients
with T1D is rare and could be due to the autoimmune
dysfunction characterizing patients with T1D. The clin-
ical significance of these autoantibodies in children with
T1D is yet to be identified in a long term larger pro-
spective studies.
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